IQM appoints BioNTech executive Dr Sierk Poetting as COB
(HPCWire) IQM Quantum Computers (IQM) announced a new chairman to accelerate business growth and focus on its global expansion and scalable production.
IQM announced that Dr. Sierk Poetting, COO of BioNTech SE, has been appointed as the Chairman of the Board at IQM Quantum Computers. Poetting is experienced in the rapid transformation of fast-growing companies and globally expanding businesses, areas needed for IQM to scale through the next development phase. Poetting serves as Chief Operating Officer at BioNTech SE, a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. He holds a Master of Science in Optical Sciences from the University of Arizona and a Ph.D. in Physics from the Ludwig-Maximilians University in Munich.
“Technological advances and the increasing use of big data have disrupted many technologies, including healthcare, supporting the earlier detection of diseases and the development of more efficient treatments. IQM is an innovative company from Europe with regards to technological advancements in quantum computing, and I am looking forward to supporting them on their growth trajectory,” said Sierk Poetting.
IQM provides on-premises quantum computers for supercomputing data centers and research labs and offers full access to its hardware. For industrial customers, IQM delivers quantum advantage through a unique, application-specific, co-design approach.
IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium (Q-Exa) is building Germany’s quantum computer, which will be integrated into an HPC supercomputer to create an accelerator for future scientific research. IQM has